As a minimum, a new treatment or drug will seek evidence to support that it is NOT INFERIOR to the standard of care, which the company used to gain approval. There is no point in knowingly creating an inferior product when targeting the same market.
It's only if you know you have a superior product that you walk into a head-to-head, and especially to do it before your product has gained licensing. Failure can be catastrophic.
CU6 Price at posting:
$6.73 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)